Back to top

Image: Bigstock

Inter Parfums (IPAR) Q4 Earnings Meet Estimates, View Down

Read MoreHide Full Article

Inter Parfums, Inc. (IPAR - Free Report) delivered fourth-quarter 2019 results, with the top and the bottom line meeting the Zacks Consensus Estimate. Moreover, earnings were flat year on year. Nevertheless, revenues rose on a year-over-year basis. Sturdy brand performances across U.S. operations fueled the metric.

Quarter in Details

The company posted earnings per share of 26 cents, in line with the Zacks Consensus Estimate.

Net sales for the quarter amounted to $177.8 million, up 0.3% on a year-over-year basis. Moreover, revenues were in line with the consensus mark. At comparable-currency exchange rates, net sales inched up 1.5%. Growth across the U.S. operations boosted sales in the reported quarter.

In U.S. based operations, net sales rose 14.7% to $48.7 million. Net sales in the European-based operations amounted to $129.1, down 4.2% year on year.

Gross profit amounted to $114.7 million, down 2.1% year on year. Further, gross margin was 64.5%, down 160 basis points (bps).   

SG&A expenses amounted to $102.3 million, down 3.9% year on year. Also, as a percentage of net sales, SG&A expenses were 57.6%. The metric declined from 60.1% in the prior-year quarter.

Operating income came in at $12.3 million, up 16.5% year on year. Further, operating margin was 6.9%, up 90 bps.

Inter Parfums, Inc. Price, Consensus and EPS Surprise

 

Inter Parfums, Inc. Price, Consensus and EPS Surprise

Inter Parfums, Inc. price-consensus-eps-surprise-chart | Inter Parfums, Inc. Quote


Other Financial Aspects

The company ended the quarter with cash and cash equivalents of $192.4 million, long-term debt (excluding current portion) of $10.7 million and total shareholder equity of $468 million.

The company declared a quarterly dividend of 33 cents. The dividend will be paid out on Apr 15, 2020 to shareholders on record as on Mar 31, 2020.

Guidance

In 2020, management expects sales to be aided by fragrance launches at key brands. The company launched a new women’s fragrance range by Coach brand in the beginning of 2020 in Europe. Also, Inter Parfums plans to launch women’s scent for Montblanc sometime this spring in the region. Moreover, management hopes to launch scents from brands like Jimmy Choo and Kate Spade New York during the year in Europe. For U.S. operations, the company plans to launch new fragrance under the GUESS and Hollister brands sometime this spring. Moreover, Inter Parfums is optimistic about the debut of a number scents from brands like Anna Sui and Graff in the region.

That said, the company is mindful of the recent outbreak of coronavirus. Inter Parfums has been witnessing significant decline in air travel along with reduced customer traffic in major shopping and tourist destinations. Consequently, management delayed various launches toward the end of 2020. Management stated that if the prevalence of coronavirus impact is limited to the initial few months of 2020, it expects net sales and net income to be in line with 2019 numbers. In 2019, Inter Parfums delivered net sales of $713.5 million, whereas net income was $1.90 per share. The company had earlier envisioned net sales to be roughly $742 million in 2020, while net income was earlier expected to be nearly $2.00 per share.

Price Performance

Shares of this Zacks Rank #3 (Hold) company have dropped 2.5% in the past six months compared with the industry’s decline of 27.6%.

 



Don’t Miss These Solid Consumer Staple Bets

Lamb Weston (LW - Free Report) , with a Zacks Rank #2 (Buy), has long-term earnings per share growth rate of 8.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Hershey Company (HSY - Free Report) , which carries a Zacks Rank #2, has a long-term earnings growth rate of 7.7%.

e.l.f. Beauty Inc. (ELF - Free Report) , which carries a Zacks Rank #2, has a long-term earnings growth rate of 3.8%.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>